title: Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
abstract: The authors found that buspirone added to the treatment of 33 patients with obsessive-compulsive disorder who were refractory to the serotonin reuptake inhibitor fluvoxamine was no better than placebo in reducing obsessive-compulsive, depressive, or anxiety symptoms. This finding suggests that addition of buspirone to ongoing fluvoxamine therapy is not an effective treatment strategy for most patients with obsessive-compulsive disorder.
authors: Clinical Neuroscience Research Unit, Yale University School of Medicine, Connecticut Mental Health Center, New Haven 06519.
authors: C J
authors: CJ
authors: McDougle
authors: W K
authors: WK
authors: Goodman
authors: J F
authors: JF
authors: Leckman
authors: J C
authors: JC
authors: Holzer
authors: L C
authors: LC
authors: Barr
authors: E
authors: E
authors: McCance-Katz
authors: G R
authors: GR
authors: Heninger
authors: L H
authors: LH
authors: Price
mesh_terms: D000328:Adult; D001008:Anxiety Disorders / Q000175:diagnosis / Q000523:psychology; D002065:Buspirone / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000175:diagnosis / Q000523:psychology; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D010919:Placebos; D011569:Psychiatric Status Rating Scales
chemical_list: D010919:Placebos; D016666:Fluvoxamine; D002065:Buspirone